Form 4: Akero Therapeutics Executive Sells Shares to Cover Tax Obligations

Catriona Yale, Chief Development Officer of Akero Therapeutics, sold 614 shares of common stock on March 12, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On March 12, 2025, Catriona Yale, the Chief Development Officer of Akero Therapeutics, sold 614 shares of the company's common stock.
• The sale was executed at a price of $44.88 per share.
• This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Yale directly owns 95,034 shares of Akero Therapeutics.
• The sale was automatic under the issuer's 'sell-to-cover' policy and not at the discretion of the reporting person.

Sentiment

Score: 5

Explanation: The Form 4 filing represents a routine transaction (sell-to-cover) and doesn't inherently indicate positive or negative sentiment. It's a neutral event.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives and do not necessarily indicate a negative outlook on the company's future.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates